AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial

Recent reporting across multiple financial and medical news outlets details clinical trial developments regarding treatments for inflammatory bowel disease from AbbVie. The central development involves AbbVie presenting data for ABBV-466, a novel dual-targeting therapy. According to these reports, the treatment demonstrated higher endoscopic remission rates in moderate to severe Crohn's disease compared to either anti-IL-23 or anti-beta-7 monotherapy. Additional details from grafa.com state that the ABBV-466 therapy achieved a specific remission metric of forty point five percent in Crohn's patients. Coverage from Yahoo Finance and MedPage Today further highlights related data presented at the UEGW 2026 conference. This includes long-term clinical and endoscopic outcomes across inflammatory bowel disease for established therapies like Skyrizi, which is risankizumab, and Rinvoq, which is upadacitinib.

MedPage Today specifically notes that subcutaneous risankizumab induction improved outcomes in Crohn's disease patients. Fierce Biotech frames the ABBV-466 trial outcome as a next-generation combination beating Skyrizi in the phase 2 trial setting. The reporting collectively focuses on these clinical findings and trial data presentations originating from the medical meeting. The context provided by the headlines situates these data releases within ongoing research and medical presentations at the UEGW 2026 event. AbbVie is utilizing this platform to showcase both pipeline assets like the dual-targeting ABBV-466 and extended trial outcomes for approved blockbusters like Skyrizi and Rinvoq. The comparison between the novel dual-targeting approach and established monotherapies forms a significant part of the scientific discourse captured in the updates.

Coverage does not yet specify the complete commercial timeline for ABBV-466 or the full regulatory roadmap following the phase 2 data release. Observers and stakeholders tracking these developments will monitor future medical congresses and corporate announcements for additional phase data. The headlines indicate that ongoing evaluation of subcutaneous risankizumab induction, alongside the progression of ABBV-466, remains a focal point for the company's inflammatory bowel disease portfolio. Coverage does not yet specify when subsequent late-stage trials will officially commence or conclude. Further updates will depend on official disclosures from AbbVie and additional presentations in specialized medical literature.